iPLA₂γ KO mice show increased glomerular autophagy. by Andrey V. Cybulsky (4007012)

Subjects:

UHPLC-MS CKO vs K5Cre results. by Kevin J. Mills (9270966)

Subjects:

Uncropped raw western blot images. by Kevin J. Mills (9270966)

Subjects:

LC-IMS-CID-MS CKO vs K5Cre results. by Kevin J. Mills (9270966)

Subjects:

Phospholipid metabolism CKO vs K5Cre Reactome. by Kevin J. Mills (9270966)

Subjects:

Localization and conditional deletion of C/EBP in SKH1 mouse epidermis. by Kevin J. Mills (9270966)

Subjects:

Conditional deletion of C/EBP in epidermis results in downregulation of transcripts and pathways associated with lipid biosynthesis in epidermis. by Kevin J. Mills (9270966)

Subjects:

The strength of the commute time-functional connectivity relationship demonstrates weak pathological significance and weak dependency on age. by Rostam M. Razban (22232522)

“…The corresponding Kolmogorov-Smirnov pairwise tests are not significant (S5 Table in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0331085#pone.0331085.s001" target="_blank">SI</a>). …”

DDC for four anticoagulants from 2019 to 2023. by Wei Luo (80175)

Subjects:

Presentation 1_Decreased brain-derived neurotrophic factor expression in chronic kidney disease: integrated clinical and experimental evidence.pptx by Juan Chen (61123)

“…</p>Conclusion<p>This study integrated meta-analysis, murine model validation, and single-cell transcriptomic profiling to demonstrate a significant reduction of BDNF in CKD. Furthermore, renal BDNF expression decreased locally, predominantly originating from proximal tubule cells, macrophages, and podocytes, possibly epigenetically inhibited by the upregulation of lnc RNA Bdnf-as.…”

Inpatient utilization of anticoagulants from 2019 to 2023. by Wei Luo (80175)

Subjects:

Outpatient utilization of anticoagulants from 2019 to 2023. by Wei Luo (80175)

Subjects:

Utilization of anticoagulants from 2019 to 2023. by Wei Luo (80175)

Subjects:

The expenditure on anticoagulants in the period of 2019-2023(million CNY). by Wei Luo (80175)

Subjects:

Screening for gHgLgO interaction partners reveals decreased binding of the gO249 mutant to cell surfaces. by Lena Thiessen (17605194)

Positioning errors of different algorithms on the a multi-modal and multi-scenario dataset for ground robots dataset. by Hongliang Zou (20707270)

Subjects:

Specific parameters of the test sequence in the a multi-modal and multi-scenario dataset for ground robots dataset. by Hongliang Zou (20707270)

Subjects:

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”